公开(公告)号：US07951933B2

公开(公告)日：2011-05-31

申请号：US11056106

申请日：2005-02-10

Applicant: Jun Li ,  Xiang Li ,  Baerbel LoSacco ,  Zhenhao Qi

Inventor： Jun Li ,  Xiang Li ,  Baerbel LoSacco ,  Zhenhao Qi

IPC: C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12P19/34 ,  C12N5/00 ,  C12N5/02

CPC classification number: C07K14/70596 ,  A61K38/00

Abstract: The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.

Abstract translation: 本发明提供了本文中称为CD38JL的基本上纯化的多肽，其是由SEQ ID NO：1的多肽或其片段组成的CD38剪接变体。 本发明还提供了治疗预防和诊断与CD38JL表达相关的疾病的方法。

公开(公告)号：US07944940B2

公开(公告)日：2011-05-17

申请号：US12452161

申请日：2007-06-22

Applicant: Xiao-Jun Ma ,  Yong He ,  Zhigang Zhang ,  Huanqiang Zhang ,  Jun Li ,  Charles Chunaming Wang

Inventor： Xiao-Jun Ma ,  Yong He ,  Zhigang Zhang ,  Huanqiang Zhang ,  Jun Li ,  Charles Chunaming Wang

IPC: H04L12/413

CPC classification number: H04W74/085

Abstract: A method and apparatus are described for gaining access to a communication medium in a contention-based network, including determining a slot count based on a number of stations in the contention-based network, adjusting the slot count, initiating a frame transmission when the slot count reaches a predetermined value and wherein said number of stations and an address queue are adjusted to reflect a priority. Further, a method and apparatus are described for gaining access to a communication medium in a contention-based network, including receiving a slot count based on a number of stations in the contention-based network, adjusting the slot count, initiating a frame transmission when the slot count reaches a predetermined value and wherein said number of stations and an address queue are adjusted to reflect a priority.

Abstract translation: 描述了一种用于在基于竞争的网络中获取对通信介质的访问的方法和装置，包括基于在基于竞争的网络中的站数量来确定时隙计数，调整时隙计数，当时隙发起帧传输 计数达到预定值，并且其中调整所述站数和地址队列以反映优先级。 此外，描述了一种用于在基于竞争的网络中获取对通信介质的访问的方法和装置，包括基于在基于竞争的网络中的站点数目接收时隙计数，调整时隙计数，启动帧传输， 时隙计数达到预定值，并且其中所述站数和地址队列被调整以反映优先级。

公开(公告)号：US07939734B1

公开(公告)日：2011-05-10

申请号：US10873996

申请日：2004-06-14

Applicant: Jun Li ,  Meyya Meyyappan ,  Alan M. Cassell

Inventor： Jun Li ,  Meyya Meyyappan ,  Alan M. Cassell

IPC: G01F1/64 ,  G01N27/26 ,  G01N33/543 ,  G01N33/553 ,  G01N33/53 ,  G01R31/26 ,  C12Q1/00 ,  C12M1/00 ,  C12M1/34

CPC classification number: G01N33/54373 ,  G01N27/3277 ,  Y10S436/806 ,  Y10S977/702 ,  Y10S977/742 ,  Y10S977/745 ,  Y10S977/746 ,  Y10S977/789 ,  Y10S977/904 ,  Y10S977/932 ,  Y10S977/953

Abstract: Method and system for detecting presence of biomolecules in a selected subset, or in each of several selected subsets, in a fluid. Each of an array of two or more carbon nanotubes (“CNTs”) is connected at a first CNT end to one or more electronics devices, each of which senses a selected electrochemical signal that is generated when a target biomolecule in the selected subset becomes attached to a functionalized second end of the CNT, which is covalently bonded with a probe molecule. This approach indicates when target biomolecules in the selected subset are present and indicates presence or absence of target biomolecules in two or more selected subsets. Alternatively, presence of absence of an analyte can be detected.

Abstract translation: 用于检测流体中选定子集或几个选定子集中的每一个中生物分子的存在的方法和系统。 两个或多个碳纳米管（“CNT”）的阵列中的每一个在第一CNT端连接到一个或多个电子器件，每个电子器件感测当所选子集中的靶生物分子附着时产生的所选电化学信号 涉及与探针分子共价结合的CNT的官能化第二末端。 该方法表明所选子集中的目标生物分子存在并且指示在两个或更多个选定子集中存在或不存在靶生物分子。 或者，可以检测到不存在分析物。

公开(公告)号：US20110086857A1

公开(公告)日：2011-04-14

申请号：US12901614

申请日：2010-10-11

Applicant: Percy H. Carter ,  Robert J. Cherney ,  Victor W. Rosso ,  Jun Li

Inventor： Percy H. Carter ,  Robert J. Cherney ,  Victor W. Rosso ,  Jun Li

IPC: A61K31/53 ,  C07D487/04 ,  A61P35/00 ,  A61P3/04 ,  A61P3/10 ,  A61P3/00 ,  A61P25/00 ,  A61P25/04 ,  A61P9/10 ,  A61P9/12 ,  A61P17/06 ,  A61P17/00 ,  A61P19/02 ,  A61P9/04 ,  A61P9/00 ,  A61P29/00 ,  A61P31/18 ,  A61P1/00 ,  A61P13/12 ,  A61P25/28

CPC classification number: A61K31/53 ,  C07D487/04

Abstract: The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The present disclosure also provides processes for preparing compounds of Formula (I) as provided herein, including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide. Compounds that are useful intermediates of the process are also provided herein.

Abstract translation: 本发明提供新的拮抗剂：N - （（1R，2S，5R）-5-（叔丁基氨基）-2 - （（S）-3-（7-叔丁基吡唑并[1,5-a] 1,3,5]三嗪-4-基氨基）-2-氧代吡咯烷-1-基）环己基）乙酰胺：或其药学上可接受的盐，溶剂合物或前药，具有意想不到的双重CCR-2和CCR-5受体活性。 还公开了结晶形式，代谢物，含有其的药物组合物和使用其作为治疗炎性疾病，过敏性，自身免疫性，代谢性，癌症和/或心血管疾病的药剂的方法。 本公开还提供了制备本文提供的式（I）化合物的方法，包括N - （（1R，2S，5R）-5-（叔丁基氨基）-2 - （（S） 叔丁基吡唑并[1,5-a] [1,3,5]三嗪-4-基氨基）-2-氧代吡咯烷-1-基）环己基）乙酰胺。 本文还提供了该方法有用中间体的化合物。

公开(公告)号：US20110077298A1

公开(公告)日：2011-03-31

申请号：US12994862

申请日：2009-05-31

Applicant: Feihu Chen ,  Jingbo Shi ,  Yuan Wang ,  Jun Li ,  Juan Shen ,  Jingjing Ruan ,  Fanrong Wu

Inventor： Feihu Chen ,  Jingbo Shi ,  Yuan Wang ,  Jun Li ,  Juan Shen ,  Jingjing Ruan ,  Fanrong Wu

IPC: A61K31/215 ,  C07C69/587 ,  C07C63/00 ,  A61K31/19 ,  C07C233/01 ,  A61K31/16 ,  C07C229/52 ,  A61K31/195 ,  A61P35/00 ,  A61P17/00

CPC classification number: C07C69/734 ,  C07C219/34 ,  C07C235/38 ,  C07C255/55 ,  C07C255/60 ,  C07C403/20 ,  C07C2601/16

Abstract: The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.

Abstract translation: 本发明涉及类视黄醇衍生物及其药物组合物及其用途。 本发明的化合物能够预防或治疗诸如急性白血病，慢性白血病，多发性骨髓瘤和淋巴瘤，实体瘤如肝癌，直肠癌，乳腺癌和食道癌等血液肿瘤和皮肤病，例如 牛皮癣和痤疮。

公开(公告)号：US20110038308A1

公开(公告)日：2011-02-17

申请号：US12681118

申请日：2008-10-06

Applicant: Yi Song ,  Geng Wu ,  Jun Li ,  Neng Wang ,  Kathiravetpillai Sivanesan ,  Sang-Youb Kim ,  Rose Hu ,  David Paranchych ,  Lai-King Tee

Inventor： Yi Song ,  Geng Wu ,  Jun Li ,  Neng Wang ,  Kathiravetpillai Sivanesan ,  Sang-Youb Kim ,  Rose Hu ,  David Paranchych ,  Lai-King Tee

IPC: H04W40/00

CPC classification number: H04B7/0408 ,  H04B7/0695 ,  Y02D70/25 ,  Y02D70/444

Abstract: To perform wireless communications in a wireless network, at least two spatial beams are formed within a cell segment, where the at least two spatial beams are associated with different power levels. The at least two spatial beams are swept across the cell segment according to a sweep pattern. In some implementations, multiple antenna assemblies can be used, where each antenna assembly has plural antenna elements. A lower one of the antenna assemblies can be used to form high and lower power beams, and an upper one of the antenna assemblies can be used to communicate backhaul information, for example.

Abstract translation: 为了在无线网络中执行无线通信，在小区段内形成至少两个空间波束，其中至少两个空间波束与不同的功率电平相关联。 所述至少两个空间光束根据扫描图案扫过所述细胞片段。 在一些实施方案中，可以使用多个天线组件，其中每个天线组件具有多个天线元件。 天线组件中的较低的一个可用于形成高功率和低功率光束，并且天线组件中的上部天线组件可用于例如通信回程信息。

公开(公告)号：US07875404B2

公开(公告)日：2011-01-25

申请号：US11596607

申请日：2005-06-30

Applicant: Christopher W. Moore ,  Jun Li ,  Paul Kohl

Inventor： Christopher W. Moore ,  Jun Li ,  Paul Kohl

IPC: H01M8/10

CPC classification number: H01M4/92 ,  H01M4/8605 ,  H01M4/90 ,  H01M8/0289 ,  H01M8/1004 ,  H01M8/1011 ,  H01M8/1016 ,  H01M8/1023 ,  H01M8/1027 ,  H01M8/103 ,  H01M8/1039 ,  Y02E60/523

Abstract: Fuel cells, fuel cell membranes, micro-fuel cells, and methods of fabricating each, are disclosed.

Abstract translation: 公开了燃料电池，燃料电池膜，微型燃料电池及其制造方法。

公开(公告)号：US20100327273A1

公开(公告)日：2010-12-30

申请号：US12918691

申请日：2009-02-19

Applicant: Chang Ming Li ,  Jun Li ,  Beng Ong ,  Qin Fang

Inventor： Chang Ming Li ,  Jun Li ,  Beng Ong ,  Qin Fang

IPC: H01L51/30 ,  H01L51/40 ,  C07D495/14 ,  C08G73/06

CPC classification number: H01L51/0036 ,  C07D495/14 ,  C08G61/126 ,  H01L51/0043 ,  H01L51/0545

Abstract: An organic compound represented by the following general formula (I) wherein n is an integer from 1 to 500, inclusive, and R1 and R2 are each independently a moiety having an atom length of from about 8 atoms to about 20 atoms.

Abstract translation: 由以下通式（I）表示的有机化合物，其中n为1至500的整数，包括1和500，并且R 1和R 2各自独立地为原子长度为约8至约20个原子的部分。

公开(公告)号：US07838268B2

公开(公告)日：2010-11-23

申请号：US11740438

申请日：2007-04-26

Applicant: Jun Li ,  Xiang Li ,  Jianfei Yang ,  Kenneth Marcu

Inventor： Jun Li ,  Xiang Li ,  Jianfei Yang ,  Kenneth Marcu

IPC: C12Q1/68 ,  C12P19/34 ,  C12N5/00 ,  C12N5/02 ,  C07H21/04

CPC classification number: C12Q1/485 ,  A61K38/00 ,  C12N15/113 ,  C12N2310/14 ,  G01N2333/912 ,  G01N2500/00

Abstract: A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription.

Abstract translation: 一种调节细胞中NF-κB依赖性基因转录的方法，包括调节细胞中的IKKα蛋白活性。 本发明还提供用于调节NF-κB依赖性基因转录的siRNA组合物及其方法。

公开(公告)号：US07834178B2

公开(公告)日：2010-11-16

申请号：US11679898

申请日：2007-02-28

Applicant: Jun Li ,  Jeffrey A. Robl ,  Lawrence J. Kennedy

Inventor： Jun Li ,  Jeffrey A. Robl ,  Lawrence J. Kennedy

IPC: C07D253/065 ,  C07D253/08 ,  C07D253/10 ,  A61K31/53 ,  A61P3/06 ,  A61P3/10 ,  A61P9/02

CPC classification number: C07D253/10 ,  C07D253/07

Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.

Abstract translation: 提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。 这些新化合物具有以下结构：其立体异构体或前药或其药学上可接受的盐，其中R 1，R 2和R 3在本文中定义。